Genetics and clinical phenotypes
| . | Gene identified, n (%) . | No gene identified, n (%) . |
|---|---|---|
| United States, N = 234 | ||
| Infections only, n = 91 | 23 (25) | 68 (75) |
| Complications,* n = 143 | 50 (35) | 93 (65) |
| Sweden, N =113 with data | ||
| Infections only, n = 40 | 11 (27.5) | 29 (72.5) |
| Complications,* n = 73 | 27 (36.9) | 46 (63) |
| Iran, N = 188 with data | ||
| Infections only, n = 80 | 43 (53.7) | 37 (46.2) |
| Complications,* n = 108 | 62 (57) | 46 (42.5) |
| . | Gene identified, n (%) . | No gene identified, n (%) . |
|---|---|---|
| United States, N = 234 | ||
| Infections only, n = 91 | 23 (25) | 68 (75) |
| Complications,* n = 143 | 50 (35) | 93 (65) |
| Sweden, N =113 with data | ||
| Infections only, n = 40 | 11 (27.5) | 29 (72.5) |
| Complications,* n = 73 | 27 (36.9) | 46 (63) |
| Iran, N = 188 with data | ||
| Infections only, n = 80 | 43 (53.7) | 37 (46.2) |
| Complications,* n = 108 | 62 (57) | 46 (42.5) |
CVID complications include lymphocytic and or granulomatous infiltrations, lymphadenopathy/splenomegaly, autoimmunity, and noninfectious enteropathy.